Myriad Genetics, Inc.
MYGN
$7.33
$0.314.42%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -3.47% | 8.78% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.47% | 8.78% | |||
| Cost of Revenue | 0.98% | -0.65% | |||
| Gross Profit | -5.27% | 13.11% | |||
| SG&A Expenses | 0.14% | 2.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.51% | 0.31% | |||
| Operating Income | -86.40% | 56.90% | |||
| Income Before Tax | 92.08% | -1,024.49% | |||
| Income Tax Expenses | 1,300.00% | 99.66% | |||
| Earnings from Continuing Operations | 91.71% | -330,400.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 91.71% | -330,400.00% | |||
| EBIT | -86.40% | 56.90% | |||
| EBITDA | -768.75% | 110.96% | |||
| EPS Basic | 91.76% | -324,718.18% | |||
| Normalized Basic EPS | -87.33% | 53.28% | |||
| EPS Diluted | 91.76% | -324,718.18% | |||
| Normalized Diluted EPS | -87.33% | 53.28% | |||
| Average Basic Shares Outstanding | 0.65% | 1.20% | |||
| Average Diluted Shares Outstanding | 0.65% | 1.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||